Rapid Micro Biosystems, Inc. (RPID) Insider Trading Activity

NASDAQ$0.685-0.01 (-1.45%)
Market Cap
$31.6M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
748 of 849
Rank in Industry
96 of 107

RPID Insider Trading Activity

RPID Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$1,138,003
14
100

Related Transactions

Wilson John J. AddingtonCHIEF OPERATING OFFICER
0
$0
3
$80,101
$-80,101
WIRTJES SEAN MCHIEF FINANCIAL OFFICER
0
$0
3
$122,785
$-122,785
Spignesi Robert G. Jr.PRESIDENT AND CEO
0
$0
3
$271,168
$-271,168
Longitude Capital Partners II, LLC10 percent owner
0
$0
5
$663,949
$-663,949

About Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation …

Insider Activity of Rapid Micro Biosystems, Inc.

Over the last 12 months, insiders at Rapid Micro Biosystems, Inc. have bought $0 and sold $1.14M worth of Rapid Micro Biosystems, Inc. stock.

On average, over the past 5 years, insiders at Rapid Micro Biosystems, Inc. have bought $165,663 and sold $666,980 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 9,120 shares for transaction amount of $9,484 was made by PEI MELINDA LITHERLAND (director) on 2024‑12‑05.

List of Insider Buy and Sell Transactions, Rapid Micro Biosystems, Inc.

2026-03-11SaleWIRTJES SEAN MCHIEF FINANCIAL OFFICER
7,480
0.0166%
$4.32
$32,299
-57.08%
2026-03-11SaleWilson John J. AddingtonCHIEF OPERATING OFFICER
9,603
0.0214%
$4.32
$41,467
-57.08%
2026-03-10SaleSpignesi Robert G. Jr.PRESIDENT AND CEO
17,922
0.0396%
$4.11
$73,686
-54.48%
2026-02-20SaleWIRTJES SEAN MCHIEF FINANCIAL OFFICER
17,254
0.0393%
$3.92
$67,687
-49.10%
2026-02-20SaleWilson John J. AddingtonCHIEF OPERATING OFFICER
5,403
0.0123%
$3.92
$21,196
-49.10%
2026-02-19SaleSpignesi Robert G. Jr.PRESIDENT AND CEO
38,327
0.0806%
$3.89
$148,912
-50.00%
2026-02-09SaleSpignesi Robert G. Jr.PRESIDENT AND CEO
12,840
0.0292%
$3.78
$48,570
-46.93%
2026-02-09SaleWIRTJES SEAN MCHIEF FINANCIAL OFFICER
6,027
0.0137%
$3.78
$22,798
-46.93%
2026-02-09SaleWilson John J. AddingtonCHIEF OPERATING OFFICER
4,610
0.0105%
$3.78
$17,438
-46.93%
2026-02-04SaleLongitude Capital Partners II, LLC10 percent owner
49,000
0.1103%
$3.88
$190,091
-48.59%
2026-02-03SaleLongitude Capital Partners II, LLC10 percent owner
27,500
0.0605%
$4.24
$116,641
-53.79%
2026-02-02SaleLongitude Capital Partners II, LLC10 percent owner
27,500
0.0629%
$4.25
$116,765
-52.03%
2026-01-30SaleLongitude Capital Partners II, LLC10 percent owner
46,000
0.1064%
$4.54
$209,001
-54.63%
2026-01-23SaleLongitude Capital Partners II, LLC10 percent owner
7,739
0.0172%
$4.06
$31,451
-51.21%
2025-07-14SaleSpignesi Robert G. Jr.PRESIDENT AND CEO
11,881
0.0281%
$3.32
$39,481
-5.00%
2025-07-11SaleSpignesi Robert G. Jr.PRESIDENT AND CEO
11,874
0.0268%
$3.33
$39,499
-9.38%
2025-07-10SaleSpignesi Robert G. Jr.PRESIDENT AND CEO
11,617
0.0267%
$3.40
$39,475
-9.50%
2025-07-09SaleSpignesi Robert G. Jr.PRESIDENT AND CEO
11,247
0.026%
$3.51
$39,480
-12.10%
2025-07-08SaleSpignesi Robert G. Jr.PRESIDENT AND CEO
10,824
0.0248%
$3.51
$38,021
-12.57%
2024-12-05PurchasePEI MELINDA LITHERLANDdirector
9,120
0.0212%
$1.04
$9,484
+184.95%
Total: 39
*Gray background shows transactions not older than one year

Insider Historical Profitability

50.09%
Spignesi Robert G. Jr.PRESIDENT AND CEO
1169848
2.5621%
$809,534.8258
+27.58%
WIRTJES SEAN MCHIEF FINANCIAL OFFICER
556194
1.2181%
$384,886.2523
+91.51%
Longitude Capital Partners II, LLC10 percent owner
0
0%
$015
<0.0001%
Bain Capital Life Sciences Investors, LLC10 percent owner
8434560
18.4725%
$5.84M10
<0.0001%
CHENE DAVID
2035441
4.4578%
$1.41M40
<0.0001%
Kollender Richard Sdirector
96718
0.2118%
$66,928.8610
+165.69%
Malloy Kirkdirector
64300
0.1408%
$44,495.6010
+156.41%
PEI MELINDA LITHERLANDdirector
54300
0.1189%
$37,575.6040
+184.43%
LOWENSTEIN INESE
10000
0.0219%
$6,920.0010
<0.0001%
*Gray background shows insiders who have made transactions during last year

RPID Institutional Investors: Active Positions

Increased Positions26+96.3%1M+7.34%
Decreased Positions9-33.33%1M-8.74%
New Positions15New824,291New
Sold Out Positions2Sold Out33,626Sold Out
Total Postitions44+62.96%15M-1.41%

RPID Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Bain Capital Life Sciences Investors, Llc$26,485.0021.09%8.43M00%2025-09-30
Abg-Wtt Global Life Science Capital Partners Gp Ltd$5,804.004.62%1.85M00%2025-09-30
Vanguard Group Inc$3,030.002.41%965,018+60,655+6.71%2025-09-30
Parkman Healthcare Partners Llc$2,868.002.28%913,44300%2025-09-30
Schonfeld Strategic Advisors Llc$2,030.001.62%646,579-391,089-37.69%2025-09-30
Advent International, L.P.$1,814.001.44%577,77700%2025-09-30
Blackrock, Inc.$1,519.001.21%483,871+7,054+1.48%2025-09-30
Geode Capital Management, Llc$643.000.51%204,687+608+0.3%2025-09-30
Evernest Financial Advisors, Llc$629.000.5%200,234+156,234+355.08%2025-09-30
Renaissance Technologies Llc$346.000.28%110,187-800-0.72%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.